A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients | Zendy

Hanyan Xu | Zendy; Adam Abdul Hakeem Baidoo | Zendy; Shanshan Su | Zendy; Junru Ye | Zendy; Chengshui Chen | Zendy; Yupeng Xie | Zendy; Luca Bertolaccini | Zendy; Mahmoud Ismail | Zendy; Biagio Ricciuti | Zendy; Calvin S.H. Ng | Zendy; Raja M. Flores | Zendy; Yuping Li | Zendy

Open Access

A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients

Author(s) -

Hanyan Xu,

Adam Abdul Hakeem Baidoo,

Shanshan Su,

Junru Ye,

Chengshui Chen,

Yupeng Xie,

Luca Bertolaccini,

Mahmoud Ismail,

Biagio Ricciuti,

Calvin S.H. Ng,

Raja M. Flores,

Yuping Li

Publication year - 2019

Publication title -

translational lung cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.474

H-Index - 41

eISSN - 2226-4477

pISSN - 2218-6751

DOI - 10.21037/tlcr.2019.03.10

Subject(s) - medicine , gefitinib , adenocarcinoma , lung cancer , epidermal growth factor receptor , mutation , oncology , lung , cancer research , cell free fetal dna , prospective cohort study , gene mutation , tyrosine kinase inhibitor , cancer , pathology , gene , biology , genetics , pregnancy , fetus , prenatal diagnosis

Previous studies have shown that there are different methods used to detect the epidermal growth factor receptor ( EGFR ) mutation status in plasma cell-free DNA (cfDNA) for advanced lung adenocarcinoma patients including the ADx-Amplification Refractory Mutation System (ADx-ARMS). We explored the performance of the ADx-ARMS in detecting the EGFR mutations in cfDNA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research